Lund, Sweden, 11:00 CET, 211011 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, announced today that changes are being made to the management team. On December 1, 2021, Michael Wrang Mortensen will begin the newly installed role of Executive Vice President Research & Development and Operations.
Michael holds a PhD degree in Chemistry from University of Copenhagen and an executive MBA from the AVT Business School in Denmark. Michael has 15 years of experience from the Medical Device and Healthcare industry with solid leadership and management experience within global innovation, product development and operations. Michael joins BONESUPPORT from his role as Director Development & Supply at Nanovi A/S.
The newly installed role means that Dr. Michael Diefenbeck leaves the responsibility for R&D to fully focus on his role as Chief Medical Officer and EVP Medical Affairs & Clinical Affairs and that Johan Olsson leaves his role as EVP Manufacturing & Supply for a role as Senior Advisor.
For more information contact:
BONESUPPORT HOLDING AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70
+46 (0) 708 76 87 87
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 181 million in 2020. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.